Core Viewpoint - The newly revised "Regulations on the Implementation of the Drug Administration Law" will take effect on May 15, addressing the needs of the innovative drug industry in China, which has rapidly developed into the second-largest pharmaceutical market globally and is now in the second tier of global drug research and development. Group 1: Highlights of the New Regulations - Highlight 1: "Data Protection" Expanded to New Chemical Entities - The new regulations extend data protection to drugs containing new chemical entities, providing a protection period of up to 6 years for undisclosed trial data, encouraging drug innovation while balancing the relationship between innovative and generic drugs [5][4]. - Highlight 2: Institutionalization of the "Market Exclusivity" System - The new regulations establish a formal market exclusivity system for innovative drugs, granting up to 2 years of exclusivity for new pediatric drugs and up to 7 years for rare disease treatments, thus providing administrative protection for innovation [6][7]. - Highlight 3: Conditional Opening of Drug Contracted Segment Production - The regulations clarify conditions under which segmented production can be contracted, allowing for more flexibility in drug manufacturing while addressing potential risks associated with quality management and regulatory compliance [8][10]. - Highlight 4: Strengthening Oversight of Overseas New Drug Batch Approvals - The regulations enhance the management of commercial-scale batches of drugs approved overseas, allowing them to be sold in China after passing GMP compliance checks, thereby ensuring drug safety while meeting urgent clinical needs [11][10].